Disease Foundations Are Finding Their Way In New Research Relationships
This article was originally published in The Pink Sheet Daily
Executive Summary
Disease foundations have realized that funding basic research is not enough to serve their patient groups, but forging those later-stage relationships can be tricky and all parties involved are developing new flexibilities, panelists at the BIO annual meeting said June 21 in Boston.
You may also be interested in...
Sanofi Taps Fox Foundation For Parkinson’s Drug Development
Sanofi and the Michael J. Fox Foundation have teamed up on the development of a treatment for cognitive deficits related to Parkinson’s disease.
Celgene Bolsters Pipeline With Avila Acquisition
Celgene will acquire the Massachusetts biotech for $350 million upfront plus $575 million in potential milestones related to Avila’s lead compound as well as other compounds to emerge from its technology platform.
Civitas’ Inhaled L-Dopa Candidate To Start Phase 1, Backed by Michael J. Fox Foundation Grant
Parkinson’s disease is crowded, but Civitas’ value proposition is attractive because the unmet need remains high, the technology shows promise, the clinical trials are straightforward and relatively rapid, and the company, a spinout of Alkermes, starts with clinically validated assets and infrastructure.